Drug Profile


Alternative Names: ABT 822; BRLP 42

Latest Information Update: 23 May 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Biorex
  • Class Anti-ischaemics; Antihyperglycaemics; Small molecules
  • Mechanism of Action Protein synthesis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Diabetic complications; Diabetic neuropathies; Ischaemic heart disorders

Most Recent Events

  • 17 May 2011 Orphazyme acquires bimoclomol from CytRx Corporation
  • 12 Oct 2004 CytRx Corporation has acquired all the clinical, pharmacological and intellectual property assets of Biorex
  • 04 Dec 2001 Abbott Laboratories returned all rights to bimoclomol to Biorex
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top